Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks to buy according to hedge funds. Earlier on June 6, a significant advancement in drug discovery was announced with the ...

Describe the bug in pipeline_flux.py The docstring says prompt_2 is optional but it is not declared as Optional [] and has no default None value Minor issue, could be in other pipelines too def encode ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to ...

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. Quiver AI Summary MIT and Recursion have released Boltz-2 ...

The MIT model predicts molecular binding affinity at newfound speed and accuracy, offering a powerful tool for commercial drug discovery.

Near-term catalysts include phase 2 TUPELO trial data for REC-4881 in Familial Adenomatous Polyposis and a futility analysis for REC-2282 in neurofibromatosis type 2, both in H1'25.

Polaris 3.0 was developed using extensive feedback from actual patients and their healthcare providers from over 1.85 million patient calls.

Recursion also announced that the U.S. Food and Drug Administration has cleared an investigational new drug application for a Phase 1/2 clinical trial of REC-4539, a potential best-in-class LSD1 ...

In this letter, a 2-D parameter-optimized spatial finite-difference temporal differential (SFDTD) method is presented, referred to as the PO-SFDTD method. First, the dispersion characteristic of the ...